SOURCE-LINKED INTELLIGENCE
A Vision-Language Foundation Model for Precise and Comprehensive Brain Tumor Diagnosis from Preoperative Multimodal Data
arXiv · AI, language, vision and robotics · article · Sep 15, 2026 · UTC
We developed BrainVLM to classify all 12 World Health Organization (WHO) 2021 brain tumor types. BrainVLM integrates an uncertainty quantification strategy to indicate prediction reliability and a module for generating radiology reports to elucidate the clinical rationale. BrainVLM was trained on multi-modal data (MRI scans, demographics, and radiology reports) from 40,043 individuals. It was validated on 5,211 patients with pathologically confirmed brain tumors, including 3,877 held-out patients from the primary hospital and 1,334 patients from 11 independent hospitals. We further conducted t
Read original source ↗ Open in workspace
- recordType
- paper
- region
- Global
Evidence & attribution
First collected: 2026-09-20T09:01:24.920Z. This is not the publication date.
Observed changes
AIIC observation times, not verified publisher revision times. Up to eight recent revisions.
2026-09-23T23:32:26.314Z
- summary:
Background Non-invasive presurgical diagnosis of brain tumor types from Magnetic Resonance Imaging (MRI) is essential but challenging due to overlapping imaging features across tumor types, inter-observer variability, and the extensive training required for expertise. We aimed to develop an MRI-based Artificial Intelligence (AI) model for automatic and reliable brain tumor classification with diagnostic uncertainty quantification and radiology reports generation. Methods We developed BrainVLM to classify all 12 World Health Organization (WHO) 2021 brain tumor types. BrainVLM integrates an unce → We developed BrainVLM to classify all 12 World Health Organization (WHO) 2021 brain tumor types. BrainVLM integrates an uncertainty quantification strategy to indicate prediction reliability and a module for generating radiology reports to elucidate the clinical rationale. BrainVLM was trained on multi-modal data (MRI scans, demographics, and radiology reports) from 40,043 individuals. It was validated on 5,211 patients with pathologically confirmed brain tumors, including 3,877 held-out patients from the primary hospital and 1,334 patients from 11 independent hospitals. We further conducted t